C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 5.89 HKD -2.32% Market Closed
Market Cap: 2.1B HKD

Net Margin
Cutia Therapeutics

-188.7%
Current
-509%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-188.7%
=
Net Income
-472.3m
/
Revenue
250.3m

Net Margin Across Competitors

No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.1B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
13.71 HKD
Undervaluation 57%
Intrinsic Value
Price
C
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-188.7%
=
Net Income
-472.3m
/
Revenue
250.3m
What is the Net Margin of Cutia Therapeutics?

Based on Cutia Therapeutics's most recent financial statements, the company has Net Margin of -188.7%.

Back to Top